title: Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
abstract: OBJECTIVE
  To evaluate the contribution of preoperative serum tumor markers to manage borderline ovarian tumors (BOT).
  
  
  METHODS
  Retrospective multicentre study including 317 BOT. Serum tumor marker levels of CA125, CA19-9, CEA, and CA15-3 were determined by radio-immunoassay.
  
  
  RESULTS
  Among 181 women with serous BOT and 136 women with mucinous BOT, respectively 55 of 114 (48.2%) and 38 of 91 (41.8%) had at least one abnormal value. Women with preoperative tumor marker assays were more likely to have radical treatment (p=0.0001), full staging (p=0.004), and intra-operative histology (p<0.0001). Women with at least one abnormal tumor marker were more likely to undergo laparotomy (p=0.007), to have intra-operative histology (p=0.04) and complete staging (p=0.0008). In multivariate analysis, first-line laparoscopy was associated with abnormal tumor marker levels (OR=9.63; 95%CI=1.40-66.39; p=0.02), while laparotomy was associated with large tumors, bilateral tumors, and ascitis visible on sonography.
  
  
  CONCLUSIONS
  Serum tumor marker assays modified both preoperative assessment and surgical management of BOT.
authors.affiliation: Hôpital Tenon, AP-HP, CancerEst, Université Pierre et Marie Curie Paris VI, France.
authors.forename: C
authors.initials: C
authors.lastname: Poncelet
authors.forename: R
authors.initials: R
authors.lastname: Fauvet
authors.forename: C
authors.initials: C
authors.lastname: Yazbeck
authors.forename: C
authors.initials: C
authors.lastname: Coutant
authors.forename: E
authors.initials: E
authors.lastname: Darai
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001201:Ascites / Q000209:etiology; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D005629:Frozen Sections; D006801:Humans; D010535:Laparoscopy; D007813:Laparotomy; D016015:Logistic Models; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000150:complications / Q000601:surgery / Q000628:therapy*; D011863:Radioimmunoassay; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1